Scotland’s drug appraisal body, the Scottish Medicines Consortium (SMC),  announced its decision to approve life-extending drug Perjeta for routine use in treating secondary breast cancer on Scotland’s NHS in January. 

The decision was made following our Perjeta Now campaign, in which over 12,000 amazing supporters signed the petition to make Perjeta available. 

Scroll through our presentation below to find out what Perjeta means to people affected by breast cancer:


We’re so proud that together we made Perjeta available. Help us achieve even more by signing up to hear about our campaigns.